Large-scale database mining reveals hidden trends and future directions for cancer immunotherapy

ABSTRACT Cancer immunotherapy has fundamentally changed the landscape of oncology in recent years and significant resources are invested into immunotherapy research. It is in the interests of researchers and clinicians to identify promising and less promising trends in this field in order to rationally allocate resources. This requires a quantitative large-scale analysis of cancer immunotherapy related databases. We developed a novel tool for text mining, statistical analysis and data visualization of scientific literature data. We used this tool to analyze 72002 cancer immunotherapy publications and 1469 clinical trials from public databases. All source codes are available under an open access license. The contribution of specific topics within the cancer immunotherapy field has markedly shifted over the years. We show that the focus is moving from cell-based therapy and vaccination towards checkpoint inhibitors, with these trends reaching statistical significance. Rapidly growing subfields include the combination of chemotherapy with checkpoint blockade. Translational studies have shifted from hematological and skin neoplasms to gastrointestinal and lung cancer and from tumor antigens and angiogenesis to tumor stroma and apoptosis. This work highlights the importance of unbiased large-scale database mining to assess trends in cancer research and cancer immunotherapy in particular. Researchers, clinicians and funding agencies should be aware of quantitative trends in the immunotherapy field, allocate resources to the most promising areas and find new approaches for currently immature topics.

[1]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[2]  Soumen Roy,et al.  Microbiota: a key orchestrator of cancer therapy , 2017, Nature Reviews Cancer.

[3]  M. Wallack,et al.  Immunotherapy in colorectal cancer. , 1981, Missouri medicine.

[4]  E. Jaffee,et al.  Targeting neoantigens to augment antitumour immunity , 2017, Nature Reviews Cancer.

[5]  Simone Fulda,et al.  Targeting IAP proteins for therapeutic intervention in cancer , 2012, Nature Reviews Drug Discovery.

[6]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[7]  Thomas Davis,et al.  Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Teresa Villanueva Immunotherapy: T cells get a ride , 2017, Nature Reviews Cancer.

[9]  Daniel Andersson,et al.  Cellular organization and molecular differentiation model of breast cancer-associated fibroblasts , 2017, Molecular Cancer.

[10]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[11]  Israel Lowy,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[13]  S. Rosenberg,et al.  A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.

[14]  E. Chiocca,et al.  Oncolytic Viruses in Cancer Treatment: A Review , 2017, JAMA oncology.

[15]  Constantino Carlos Reyes-Aldasoro,et al.  The proportion of cancer-related entries in PubMed has increased considerably; is cancer truly “The Emperor of All Maladies”? , 2017, PloS one.

[16]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Michel Sadelain,et al.  Targeting tumours with genetically enhanced T lymphocytes , 2003, Nature Reviews Cancer.

[18]  S. Woolf The meaning of translational research and why it matters. , 2008, JAMA.

[19]  M. Pittet,et al.  The role of myeloid cells in cancer therapies , 2016, Nature Reviews Cancer.

[20]  L. Gammaitoni,et al.  Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective , 2014, Expert opinion on biological therapy.

[21]  Yiping Yang,et al.  Cancer immunotherapy: harnessing the immune system to battle cancer. , 2015, The Journal of clinical investigation.

[22]  Axel Hoos,et al.  Classification of current anticancer immunotherapies , 2014, Oncotarget.

[23]  Virapong Prachayasittikul,et al.  Exploring the epigenetic drug discovery landscape , 2017, Expert opinion on drug discovery.

[24]  Cynthia A. Brewer,et al.  ColorBrewer.org: An Online Tool for Selecting Colour Schemes for Maps , 2003 .

[25]  T. Blankenstein,et al.  Immunotherapy: target the stroma to hit the tumor. , 2005, Trends in molecular medicine.

[26]  A. Snyder,et al.  Acquired resistance to immunotherapy and future challenges , 2016, Nature Reviews Cancer.

[27]  Hongming Pan,et al.  Autophagy-associated immune responses and cancer immunotherapy , 2016, Oncotarget.

[28]  Antoni Ribas,et al.  Current developments in cancer vaccines and cellular immunotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Tak W. Mak,et al.  The current state of cancer metabolism , 2016, Nature Reviews Cancer.

[30]  J. Wolchok,et al.  Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.